GSK plc vs ZIM Integrated Shipping Services Ltd — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while ZIM Integrated Shipping Services Ltd trades at $29.95 (market cap $3.65B). The key difference: GSK plc is far larger — about 25.2× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| GSK | ZIM | |
|---|---|---|
Market Cap | $91.88B | $3.65B |
Volume | 7,730,529 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $61.18 | $30.51 |
52-Week Low | $43.24 | $12.44 |
Typical Hold Time | 93 Days | 27 Days |
Enterprise Value | $111.88B | $7.32B |
Dividend Yield | 3.9% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
ZIM trades at $30.12, up 0.43% on the day and near its 52-week high of $30.96, reflecting strong momentum. The technical outlook is bullish, supported by moving averages, while fundamentals show mixed signals with a low P/S of 0.57 and EV/EBITDA of 3.81, but declining profitability margins. Recent Q2 2026 earnings beat expectations with EPS of $0.53 versus a forecasted loss, though revenue and net income are trending lower year-over-year. Key news includes a pending $35 per share acquisition offer from Hapag-Lloyd, subject to Israeli government approval, creating significant event-driven uncertainty.
The investment case hinges on the acquisition outcome; approval could deliver immediate upside to $35, while rejection may pressure shares despite operational improvements. Risks include earnings volatility, geopolitical factors affecting the deal, and exposure to cyclical shipping rates. Analyst sentiment is cautious with no buy ratings, reflecting the binary nature of the takeover situation. The stock offers value on a sales basis but requires careful risk management due to the high-stakes merger dynamics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →